Form 4: Aquestive COO Sells Shares Under 10b5-1 Plan

Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, exercised stock options and sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, Inc. (AQST), engaged in stock transactions on October 15, 2025.
• Exercised 25,000 non-qualified stock options at an exercise price of $3.1027 per share.
• Sold 67,575 shares of common stock at a price of $7.01 per share.
• Both the option exercise and subsequent sale were executed pursuant to a Rule 10b5-1 trading plan.
• Following these transactions, Jung directly beneficially owns 240,771 shares of common stock.
• An additional 2,000 shares are indirectly beneficially owned by Jung through her spouse.

Sentiment

Score: 4

Explanation: The filing reports an insider's exercise of options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. While the sale is profitable for the insider, it represents a reduction in direct ownership. The pre-planned nature of the transaction mitigates the immediate negative signal typically associated with insider sales, leading to a neutral to slightly negative sentiment.

Positives

• The sale price of $7.01 per share is significantly higher than the option exercise price of $3.1027 per share, indicating a profitable transaction for the insider.
• The execution of transactions under a Rule 10b5-1 trading plan demonstrates pre-planned activity, reducing the immediate negative signal often associated with insider sales.

Negatives

• The transaction resulted in a net reduction of 42,575 shares in direct beneficial ownership by a key executive (25,000 acquired, 67,575 sold), which could be interpreted as a reduction in direct exposure to the company's future performance.

Future Outlook

No specific future outlook or guidance for Aquestive Therapeutics, Inc. is provided in this Form 4 filing, which focuses solely on insider transactions.

Management Comments

• This is a scheduled exercise from 10b5-1 trading plan.
• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
• This option was granted on June 10, 2021 and is fully vested.

Industry Context

This filing is specific to an individual's stock transactions and does not provide broader industry context or analysis of Aquestive Therapeutics' position within its industry.

Comparison to Industry Standards

• This filing, detailing insider stock transactions, does not provide information suitable for direct comparison to industry benchmarks, comparable companies, or specific project results.

Related Party Transactions

• Cassie Jung's spouse beneficially owns 2,000 shares of common stock indirectly.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some may view it as a routine diversification or liquidity event under a pre-planned schedule, while others might perceive it as a slight negative signal due to reduced insider holdings.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. While the sale reduces the COO's direct holdings, the pre-planned nature mitigates strong negative sentiment. There is no new fundamental company information presented in this Form 4 to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate, pending further company-specific news or financial reports.

Keywords

Aquestive Therapeutics, AQST, Cassie Jung, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Chief Operating Officer